PT - JOURNAL ARTICLE AU - YUKI NIWA AU - MAKOTO ASANO AU - TAKAYUKI NAKAGAWA AU - DAMIEN FRANCE AU - TARO SEMBA AU - YASUHIRO FUNAHASHI TI - Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models AID - 10.21873/anticanres.14693 DP - 2020 Dec 01 TA - Anticancer Research PG - 6699--6712 VI - 40 IP - 12 4099 - http://ar.iiarjournals.org/content/40/12/6699.short 4100 - http://ar.iiarjournals.org/content/40/12/6699.full SO - Anticancer Res2020 Dec 01; 40 AB - Background/Aim: There is no established standard chemotherapy after administration of the combination endocrine plus CDK4/6 inhibitor therapy for luminal-type breast cancer. We used patient-derived xenograft (PDX) models to determine the antitumor activity of eribulin and capecitabine after endocrine therapy plus CDK4/6 inhibitor. Materials and Methods: We examined the antitumor activity of fulvestrant, palbociclib, eribulin, and capecitabine in 4 luminal-type breast cancer PDX models (OD-BRE-0188, -0438, -0450, -0745). In OD-BRE-0438, we determined the antitumor activity of chemotherapy after fulvestrant–palbociclib treatment. We also performed immunohistochemical analysis to explore the effects of treatment on E-cadherin in tumor tissues. Results: Fulvestrant, fulvestrant-palbociclib and chemotherapy had antitumor activity in the 4 PDX models. In OD-BRE-0438 (the most resistant to fulvestrant–palbociclib), eribulin had superior antitumor activity to capecitabine after fulvestrant plus palbociclib. Only eribulin tended to increase E-cadherin expression. Conclusion: Eribulin had superior antitumor activity to capecitabine after fulvestrant–palbociclib in the OD-BRE-0438 model.